Phage Therapy and Pseudomonas

Bacteriophages, or phages, are viruses that specifically target and destroy bacteria. These microscopic entities outnumber all other organisms on Earth and thrive in diverse environments, including ponds, lakes, and oceans.

---

Phages exhibit a unique structure, often resembling tiny robotic explorers with a 20-sided head mounted on a tail equipped with leg-like fibers. This design enables them to attach to specific bacterial hosts, inject their genetic material, and hijack the bacterium’s machinery to produce new phages, ultimately leading to the destruction of the bacterial cell. (Microbe Notes – Bacteriophage Structure & Function)

A Brief History of Phage Therapy

The discovery of bacteriophages dates back to 1915 when British bacteriologist Frederick Twort observed their antibacterial properties. Two years later, Félix d’Hérelle independently identified these viruses and recognized their potential as antibacterial agents. D’Hérelle pioneered phage therapy, establishing treatment centers across Eastern Europe. However, the advent of antibiotics—particularly penicillin, discovered by Alexander Fleming in 1928—led to a decline in the popularity of phage therapy in Western medicine. (ScienceDirect – History of Phage Therapy)

The Resurgence of Phage Therapy Amid Antibiotic Resistance

With the alarming rise of antibiotic-resistant bacteria, phage therapy is experiencing a renaissance. Phages offer a targeted approach to combating bacterial infections, especially those resistant to conventional antibiotics. Unlike broad-spectrum antibiotics, phages can be tailored to attack specific bacterial strains, reducing collateral damage to beneficial microbiota and minimizing the risk of resistance development. (ScienceDirect – Phage Therapy and Antibiotic Resistance)

Recent Advances: Armata Pharmaceuticals’ AP-PA02
A notable advancement in phage therapy is the development of AP-PA02 by Armata Pharmaceuticals. This inhaled bacteriophage therapy targets Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis.

The Phase 2 Tailwind study demonstrated that AP-PA02 was well-tolerated and showed potential in reducing reliance on chronic antibiotics. Encouraged by these results, Armata is progressing toward a Phase 3 clinical trial, marking a significant step forward in the application of phage therapy for respiratory infections. (PR Newswire – Tailwind Study Results)

The Future of Phage Therapy

​The renewed interest in phage therapy underscores its potential as a viable alternative or adjunct to antibiotics. As research advances, phage therapy may play a crucial role in personalized medicine, offering targeted treatments for bacterial infections that are unresponsive to traditional antibiotics. Continued clinical trials and regulatory support will be essential to integrating phage therapy into mainstream medical practice. (Journal of Intensive Care – Current Status of Phage Therapy)


#PhageTherapy #Bacteriophage #Bronchiectasis #Phage #Pseudomonas #Biologic